Dynavax Technologies | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.29B 562M 2025-03
Adma Biologics USD 24.59M 5.01M 2024-12
Amgen USD 1.69B 191M 2025-03
AstraZeneca USD 5.01B 1.42B 2025-06
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Bristol-Myers Squibb USD 1.71B 129M 2025-06
Dynavax Technologies USD 106.33M 64.74M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
Glaxosmithkline GBP 2.7B 632M 2024-12
Merck USD 2.63B 104M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Novartis USD 3.44B 384M 2025-06
Pfizer USD 3.01B 1.27B 2025-03
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Roche Holding CHF 3.61B 381M 2024-12
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
TG Therapeutics USD 38.96M 3M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12


Dynavax Technologies Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Aug 2025.